Bernd Boidol serves as Chief Executive Officer of Proxygen, where he is leading a team of world-class scientists hunting for molecular glue degraders. Glue degraders are a novel class of small molecules designed to target and degrade disease-relevant proteins within cells. This approach has gained significant attention in drug discovery and development due to its potential to target proteins that are traditionally considered "undruggable". Before joining Proxygen, Bernd worked as management consultant enabling pharma companies to scale up innovative business models around new modalities. He received a BSc and MSc in Molecular Biology from the University of Vienna, Austria. In parallel to his PhD in Oncology at the Medical University of Vienna, Bernd graduated with a BSc in Business Administration at the University of Economics and Business Administration in Vienna.